Novartis's Sandoz licenses proposed multiple sclerosis biosimilar

Swiss drugmaker Novartis's Sandoz division has licensed from Polpharma Biologics a proposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news